abstract |
Various embodiments are provided that relate to variant asparaginase polypeptides having enhanced stability, pharmacodynamics, and/or reduced immunogenicity. The variant asparaginase polypeptides can be used as therapeutics in mammals including humans, canines, felines, and equines. |